In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Jasmine McCabe-Gossett began noticing mild neuropathy in her hands and feet. It quickly progressed to “one of the most ...

Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...

With these trends in view, let’s look at the 10 best mid cap biotech stocks to buy.

It is also normally present to form a protective barrier in the airways. A number of inflammatory diseases can trigger mucus production, including: Chronic bronchitis Chronic obstructive pulmonary ...

Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of the ...

and chronic inflammatory demyelinating polyneuropathy (CIDP). Citing topline data, New York-based Immunovant (NASDAQ:IMVT) said its Phase 3 MG trial for the FcRn inhibitor met its primary endpoint ...

and chronic inflammatory demyelinating polyneuropathy (CIDP). While Immunovant (NASDAQ:IMVT) lost ~14% in reaction to the readouts, shares of its major shareholder Roivant Sciences (NASDAQ:ROIV) fell ...

the biotech isn’t currently planning to file for batoclimab approval in myasthenia gravis or chronic inflammatory demyelinating polyneuropathy (CIDP). Immunovant switched its focus from ...

Participants who respond to batoclimab therapy in Period 1 (responders are defined as those achieving a ≥1 point improvement from Period 1 baseline in adjusted Inflammatory Neuropathy Cause and ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 ...